Top Markets
#1 DeFiChain DeFiChain +2,516.54%
#2 Akedo Akedo +216.88%
#3 ONFA ONFA +54.35%
#4 Metaplex Metaplex +22.47%
#5 Wrapped Krown Wrapped Krown +19.91%
#6 Talus Network Talus Network +17.28%
#7 Black Phoenix Black Phoenix +14.97%
#8 Magma Finance Magma Finance +14.63%
#9 DODO DODO +13.28%
#10 Gnosis Gnosis +12.20%
Coin of the day
DeFiChain DeFiChain
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Valbiotis SA Valbiotis SA

Valbiotis SA

ALVAL
Rang in Aktien #16324
Valbiotis SA engages in the research and development of health nutrition... Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
Aktienkurs
$0.94180721
Marktkapitalisierung
$22.26M
Veränderung (1 Tag)
0.38%
Veränderung (1 Jahr)
-14.35%
Land
FR
Handel Valbiotis SA (ALVAL)

Kategorie

Healthcare
P/S-Verhältnis für Valbiotis SA (ALVAL)
P/S-Verhältnis zum July 2026 TTM: 20.66
Laut den neuesten Finanzberichten und dem Aktienkurs von Valbiotis SA beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 20.66. Am Ende des Jahres 2023 lag das P/S-Verhältnis bei 13.17.
P/S-Verlauf für Valbiotis SA von 2015 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
2026 (TTM) 20.66 -84.94%
2024 137.18 942.04%
2023 13.17 -71.62%
2022 46.39 -77.96%
2021 210.51 1,341.15%
2020 14.61 -87.37%
2019 115.65 -24.97%
2018 154.14 -97.25%
2017 5.61K 10,113.84%
2016 54.92 355.39%
2015 12.06 0.00%
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/S-Verhältnis P/S-Verhältnis-Differenz Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
4.33 -79.03%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.86 -52.26%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
4.53 -78.07%
US
UCB SA UCB SA
UCB SA
UCB.BR
5.72 -72.33%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
16.03 -22.43%
NL